A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat[1,2], Daniel Stadlbauer[1], Shirin Strohmeier[1,3], Thi H.O. Nguyen[4], Veronika Chromikova[1], Meagan McMahon[1], Kaijun Jiang[1], Guha Asthagiri Arunkumar[1,2], Denise Jurczyszak[1,2], Jose Polanco[1,5], Maria Bermudez-Gonzalez[1], Giulio Kleiner[1], Teresa Aydillo[1], Lisa Miorin[1], Daniel Fierer[6], Luz Amarilis Lugo[6], Erna Milunka Kojic[6], Jonathan Stoever[7], Sean T. H. Liu[6], Charlotte Cunningham-Rundles[8], Philip L. Felgner[9], Thomas Moran[1], Adolfo Garcia-Sastre[1,10], Daniel Caplivski[11], Allen Cheng[12], Katherine Kedzierska[4], Olli Vapalahti[13,14,15], Jussi M. Hepojoki[13,16], Viviana Simon[1,6,10] and Florian Krammer[1]*

[1]*Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[2]*Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[3]*Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria*
[4]*Department of Microbiology & Immunology, University of Melbourne, The Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, Australia*
[5]*Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[6]*Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[7]Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, *New York, NY, USA*
[8]*Department of Pediatrics and Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[9]*Department of Physiology & Biophysics, University of California, Irvine, CA, USA*
[10]*Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, NY, USA*
[11]*Travel Medicine Program, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[12]*School of Public Health and Preventive Medicine, Monash University; Infection Prevention and Healthcare Epidemiology Unit, Alfred Health*
[13]*Department of Virology, Medicum, University of Helsinki, Helsinki, Finland*
[14]*Veterinary Biosciences, Veterinary Faculty, University of Helsinki, Helsinki, Finland*
[15]*Department of Virology and Immunology, Helsinki University Hospital (HUSLAB), Helsinki, Finland*
[16]*Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland*

*To whom correspondence should be addressed: florian.krammer@mssm.edu

Abstract

SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While molecular assays to directly detect the viral genetic material are available for the diagnosis of acute infection, we currently lack serological assays suitable to specifically detect SARS-CoV-2 antibodies. Here we describe serological enzyme-linked immunosorbent assays (ELISA) that we developed using

recombinant antigens derived from the spike protein of SARS-CoV-2. Using negative control samples representing pre-COVID 19 background immunity in the general adult population as well as samples from COVID19 patients, we demonstrate that these assays are sensitive and specific, allowing for screening and identification of COVID19 seroconverters using human plasma/serum as early as two days post COVID19 symptoms onset. Importantly, these assays do not require handling of infectious virus, can be adjusted to detect different antibody types and are amendable to scaling. Such serological assays are of critical importance to determine seroprevalence in a given population, define previous exposure and identify highly reactive human donors for the generation of convalescent serum as therapeutic. Sensitive and specific identification of coronavirus SARS-Cov-2 antibody titers may, in the future, also support screening of health care workers to identify those who are already immune and can be deployed to care for infected patients minimizing the risk of viral spread to colleagues and other patients.

Introduction

On December 31st, 2019 China reported first cases of atypical pneumonia in Wuhan, the capital of Hubei province. The causative virus was found to be a betacoronavirus, closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV-1) from 2003 and similar to *Sarbecoviruses* isolated from bats.[1,2] It was therefore termed SARS-CoV-2 and the disease it causes was named COVID19 (COronaVIrus Disease 2019).[3] The outbreak in Wuhan expanded quickly and led to the lockdown of Wuhan, the Hubei province and other parts of China. While the lockdown, at least temporarily, brought the situation under control in China, SARS-CoV-2 spread globally causing a pandemic with, so far, 1,700,000 infections and 107,000 fatalities (as of April 11th, 2020).

Nucleic acid tests that detect the SARS-CoV-2 RNA genome were quickly developed and are now widely employed to diagnose COVID19 disease.[4,5] However, there remains a great need for laboratory assays that measure antibody responses and determine seroconversion. While such serological assays are not well suited to detect acute infections, they support a number of highly relevant applications. First, serological assays allow us to study the immune response(s) to SARS-CoV-2 in a qualitative and quantitative manner. Second, serosurveys are needed to determine the precise rate of infection in an affected area, which is an essential variable to accurately determine the infection fatality rate. Third, serological assays will allow for the identification of individuals who mounted strong antibody responses and who could serve as donors for the generation of convalescent serum therapeutics. Lastly, serological assays will potentially permit to determine who is immune and who is not. This information may be very useful for deploying immune healthcare workers in a strategic manner as to limit the risk of exposure and inadvertent spread of the virus. It could also allow a certain proportion of the population that has already acquired immunity to go back to 'normal life'. Of course, parallel studies that determine which antibody titers correlate with protection are needed to support these potential measures.

Sarbecoviruses express a large (approximately 140 kDa) glycoprotein termed spike protein (S, a homotrimer), which mediates binding to host cells via interactions with the human receptor angiotensin converting enzyme 2 (ACE2).[6-8] The S protein is very immunogenic with the receptor-binding domain (RBD) being the target of many neutralizing antibodies.[9] Individuals infected with coronaviruses typically mount neutralizing antibodies, which might be associated with some level of protection for a period of months to years[10-12], and a neutralizing response has been demonstrated for SARS-CoV-2 in an individual

case from day 9 onwards.[13] Serum neutralization can be measured using replication competent virus but the process requires several days and must be conducted in biosafety level 3 laboratory containment for SARS-CoV-2. Potentially, pseudotyped viral particle based entry assays using lentiviruses or vesicular stomatitis virus could be used but these reagents are not trivial to produce. A simple solution is the use of a binding assay, e.g. an enzyme linked immunosorbent assays (ELISA), with recombinant antigen as substrate. Here we report the development of such an assay and provide a protocol for both recombinant antigen production as well as the ELISA methodology.[14] An assay based on our protocol was implemented at Mount Sinai's clinical laboratory, has received emergency use authorization from New York State and is used for screening plasma donors with high titers of antibodies to SARS-CoV-2. We have also distributed our protocol and reagents to well above 200 laboratories across the globe.

Results

Expression constructs and generation of recombinant SARS-CoV-2 proteins

We generated two different versions of the SARS-CoV-2 spike protein. The first construct expresses a full length trimeric and stabilized version of the spike protein and the second one produces only the much smaller receptor binding domain (RBD). The sequence used for both proteins is based on the genomic sequence of the first virus isolate, Wuhan-Hu-1, which was released on January 10th 2020.[1] Sequences were codon optimized for mammalian cell expression. The full-length spike protein sequence was modified to remove the polybasic cleavage site, which is recognized by furin and to add a pair of stabilizing mutations (**Figure 1**).[7,15,16] These two modifications were included to enhance the stability of the protein based on published literature.[7,15] At amino acid P1213 the sequence was fused to a thrombin cleavage site, a T4 foldon sequence for proper trimerization and a C-terminal hexahistidine tag for purification (**Figure 1**).[17,18] The sequence was cloned into a pCAGGS vector for expression in mammalian cells and into a modified pFastBac Dual vector for generation of baculoviruses and expression in insect cells. For expression of the RBD, the natural N-terminal signal peptide of S was fused to the RBD sequence (amino acid 319 to 541) and joined with a C-terminal hexahistidine tag.[19] The same vectors as for the full length S protein were used to express the RBD. In mammalian cells, the RBD domain gave outstanding yields (approximately 25-50 mg/liter culture), but expression was lower in insect cells (approximately 1.5 mg/liter culture). Clear single bands were visible when the recombinant RBD proteins were analyzed on a reducing sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), with the insect cell derived protein (iRBD) running slightly lower than the mammalian cell derived protein (mRBD) (**Figure 1**). The size difference likely reflects differences in glycan sizes between insect cells and mammalian cells. The full-length S protein was also expressed in both systems with slightly higher yields in mammalian cells (mSpike) than in insect cells (iSpike) (approximately 5 mg/liter cultures versus 0.5 mg/liter culture). The full-length protein appeared as prominent band between 135 and 190 kDa followed by a faint, second band slightly below on a reducing SDS-PAGE, the higher species likely being the full-length protein and the slightly lower species likely a cleavage product.

ELISA development

123 Initially, we tested a panel of 50 (59 for mRBD) banked human serum samples collected from study
124 participants without and with confirmed previous viral infections (e.g., hantavirus, dengue virus,
125 coronavirus NL63 – sample take 30 days post symptom onset) to establish an ELISA with our proteins.
126 These human sera were used to test the background reactivity to the SARS-CoV-2 spike in the general US
127 population covering an age range from approximately 20 to 65+ years. An initial set of four
128 plasma/serum samples from three COVID19 survivors were used to determine the reactivity of SARS-
129 CoV-2 infected individuals to the RBD and the full length spike (**Figure 2**).

130 ELISAs were performed by doing serial dilution of the individual serum samples. Values from the dilution
131 curves were used to determine the area under the curve (AUC), which was graphed. All COVID19
132 plasma/serum samples reacted strongly to both RBD and full-length spike protein while reactivity of the
133 other serum samples only yielded background reactivity (**Figure 2**). Reactivity of COVID19 sera was, in
134 general, stronger against the full-length S protein than against the RBD, likely reflecting the higher
135 number of epitopes found on the much larger spike protein. For the RBD the difference between
136 control sera and convalescent sera was larger when the mammalian cell derived protein was used as
137 compared to the insect cell derived RBD. The same was true for the full-length spike protein. Due to the
138 expanding epidemic in New York City, we tested next an additional 14 serum samples from patients with
139 acute COVID19 disease as well as convalescent participants for reactivity to mRBD and mSpike. These
140 additional data were added to **Figure 2B, 2D, 2F and 2H**. All 14 samples reacted well with both RBD and
141 spike protein. Thus, our assays allowed to clearly distinguish the sera from participants diagnosed with
142 COVID19 from those collected prior to the pandemic (e.g., collected in the fall of 2019).

143 Our initial set of negative controls included convalescent serum from a participant with a confirmed
144 NL63 infection. Importantly, this sample did not produce a signal against the SARS-CoV-2 RBD or spike
145 underscoring the specificity of our assays. Since human coronaviruses OC43, 229E, NL63 and/or HKU1
146 are responsible for a large proportion of common colds every year, cross-reactivity between SARS-CoV-2
147 and these seasonal coronaviruses is of particular importance and warranted further investigation. To
148 test how common antibodies to human corona viruses other than SARS-CoV are in our "pre-pandemic
149 serum panel", we performed ELISAs coated with spike protein of coronavirus 229E and NL63. While
150 none of the negative control sera reacted to SARS-CoV-2 RBD and spike, the majority of samples yielded
151 strong signals to the spike proteins of these two human coronaviruses (**Figure 2I and 2J**). In addition, we
152 tested 21 different batches (27 vials) of pools of different products of normal human immune globulin
153 (NHIG), intended for intravenous use and derived from >1000 donors each. None of the NHIG
154 preparations reacted with SARS-CoV-2 RBD or spike protein and the signal obtained was similar to that
155 of the three irrelevant human monoclonal antibodies (mAbs). The RBD-binding mAb CR3022 produced,
156 in contrast, a strong signal (**Figure 3A and 3B**).[20-22] Lastly, we tested panel of fifty plasma samples
157 collected from HIV positive patients banked 2008 and 2011. Again, none of the samples reacted with the
158 SARS-CoV-2 RBD or spike (**Figure 3C and 3D**).

159 **The assay can measure antibodies in serum and plasma as well as with and without heat inactivation**

160 One complexity with measuring antibodies in bodily fluids of COVID19 patients is, that infectious virus
161 could be present in the biospecimen, especially early during acute infection. One precaution that is,
162 therefore, often used to limit this risk is to heat inactivate serum or plasma for 1 hour at 56°C. To test if
163 such a heat treatment has an effect on detecting antibodies to the SARS-CoV2 RBD and spike, we
164 compared reactivity of matched non-treated and heat-treated serum samples. While slight differences

were observed, they were minimal suggesting that heat treatment has no negative impact on assay performance (**Figure 4A and B**). Similarly, we tested matched serum and plasma samples from patients with COVID19 and found negligible differences suggesting that both types of specimens can be used in the assay interchangeably (**Figure 4C and D**).

Antibody isotyping, subtyping and neutralizing activity

For the four COVID19 patient plasma/sera from our initial panel, we performed an isotyping and subtyping ELISA using the mammalian cell expressed S proteins. Strong reactivity was found for all samples for IgG3, IgM and IgA (**Figure 5A**). An IgG1 signal was detected for the majority of samples; low reactivity for IgG2 (in five samples) and IgG4 (in four samples) was also detected. Data from this isotyping ELISA suggest that the IgG response is dominated by IgG3 subtype. Furthermore, we correlated the ELISA reactivity with the neutralizing activity of sera against the USA-WA1/2020 isolate. ELISA titers and microneutralization titers correlated significantly (**Figure 5B**) with a Spearman r of 0.9279.

Discussion

Here we describe a serological method to detect seroconversion upon SARS-CoV-2 infection with high specificity and sensitivity. The method is based on reactivity to the immunogenic S protein of the virus. The method is relatively simple and quick in its execution and can be performed at biosafety level 2 level as it does not involve live virus. We have tested these methods using banked serum samples and NHIG preparations obtained from individuals before SARS-CoV-2 started to widely circulate in the US. These serum samples produced low, close to baseline signals in our ELISAs. The age range of the participants was broad, ranging from 20 to 65+ years of age and it is likely that most of these individuals had experienced infections with human coronaviruses including the alphacoronaviruses NL63 and 229E as well as the betacoronaviruses OC43 and HKU1. In fact, the majority of our negative control subjects had strong reactivity to the spike of NL63 and 229E (but showed no cross-reactivity to SARS-CoV-2 RBD and spike). We also included paired serum samples (acute and convalescent) from a participant with a laboratory confirmed coronavirus NL63 infection. Our data show that there is no or only negligible cross-reactivity from human coronaviruses to SARS-CoV-2. Of note, even infection with the human alphacoronavirus NL63, which also uses ACE2 as receptor[23], did not induce cross-reactivity. Similar findings were reported in a recent preprint where sera from negative control subjects reacted well with spike proteins from human coronavirus but not with SARS-CoV-2.[24] This is of great importance because it suggests that humans are completely naïve to SARS-CoV-2, which may explain the relatively high R_0 of SARS-CoV-2 compared to other respiratory viruses such as influenza virus.[25] It might also suggest that antibody-dependent enhancement from human coronavirus induced cross-reactive antibodies targeted at the S protein is unlikely to be the cause of the high pathogenicity of the virus in humans.[26]

Our data show strong seroconversion after natural infection with SARS-CoV-2. Results from our assays suggest that antibodies mounted upon infection target the full length S protein as well as the RBD, which is the major target for neutralizing antibodies for related viruses coronaviruses.[9] In fact, sample SARS-CoV2 #1 was tested in another study in neutralization assays and showed a neutralizing titer of 1:160.[13] In addition, we performed microneutralization assays with a subset of our samples and found excellent correlation between our ELISA titers against the spike protein and virus neutralization. Several of the sera from individuals with confirmed COVID19 showed very strong neutralizing activity with 50%

206 inhibitory concentrations in the hundreds and thousands. Thus, seroconversion might lead to protection
207 from reinfection. Of course, protection – and antibody titers correlated with protection – need to be
208 determined in the near future. In fact, studies to determine whether antibody titers correlate with
209 protection from COVID19 should be one of the highest research priorities at this time. Of note, the ELISA
210 reagents used are derived from the original sequence from Wuhan, the neutralization assays were
211 performed with USA-WA1/2020 (an Asian lineage strain) while the majority of sera were obtained from
212 subjects infected with European-lineage viruses.[27] The observed correlation between ELISA and
213 neutralization assays hints at minimal antigenic changes. Another interesting finding was, that the IgG3
214 response appeared stronger than the IgG1 response which is in contrast to e.g. the immune response to
215 influenza where usually IgG1 responses dominate.[28,29] This is of interest since IgG3 has a stronger affinity
216 to activating Fc-receptors but a shorter half-life than IgG1. We also detected strong IgA and IgM
217 responses in the blood compartment. Of note, level of reactivity and antibody isotypes closely matched
218 expected patterns based on time since symptom onset very well. Antibody isotype and subtype titers
219 were determined using specific secondary antibodies and future studies; however, need to confirm this
220 finding using independent methods.

221 We also evaluated if heat inactivation can interfere with detection of antibodies. Heat inactivation at
222 56°C is a standard precaution for work with human sera in many laboratories. A recent pre-print had
223 shown that a commercial AIE/quantum dot-based fluorescence immunochromatographic assay (AFIA,
224 KingFocus Biomedical Engineering Co.,Ltd) assays failed to detect antibodies in samples treated at 56°C
225 for 30 min.[30] We had made similar observations with a lateral flow assay from BioMedomics. However,
226 our assay was able to detect a signal in samples heat treated for 60 min at 56°C comparable to a signal
227 obtained from non-heat treated sera. Similarly, we found that matched serum and plasma samples
228 showed similar reactivity in the ELISA making it very versatile in terms of which type of specimen can be
229 used.

230 We did not formally assess specificity and sensitivity of our assay since it might be implemented with
231 different readouts (e.g. OD at a certain dilution, AUC, endpoint titer etc.) and since the assay itself will
232 slightly vary depending on the laboratory that will implement it. However, it is clear from our data that
233 the assay has a high specificity and sensitivity. In addition, our assays are able to measure a quantitative
234 titer which correlates well with neutralization of virus. This is in contrast to many commercial assays that
235 have recently become available on the market which deliver only a qualitative result. Of note, many of
236 these assays have not been independently validated and some of them have been shown to be unfit for
237 the purpose of specifically detecting seroconversion after SARS-CoV-2 infections (e.g. in the UK; Loredo,
238 Texas etc.).

239 We believe that our ELISA method will be key for serosurveys aimed at determining the real attack rate
240 and infection fatality rate in different human populations and to map the kinetics of the antibody
241 response to SARS-CoV-2. While we found seroconversion in severe, mild and asymptomatic cases, it is
242 possible that some individuals do not seroconvert or that antibody titers wane within short periods of
243 time. To be able to interpret serosurveys correctly, studies to assess the kinetics of the antibody
244 response and the rate of non-responders are urgently needed. Clinical trials with convalescent serum as
245 therapeutic have been initiated in China (e.g. NCT04264858). In addition, a recent report suggests that
246 compassionate use of these interventions could be successful.[31] Screening potential plasma donors for
247 high antibody titers using our assay is faster and easier than performing standard neutralization assays
248 in BSL3 containment laboratories. Our assay has already been implemented for this purpose in Mount

249 Sinai's Clinical Laboratory Improvement Amendments (CLIA) regulated clinical laboratory and has
250 received emergency use authorization from New York State. Indeed, more than 20 patients with
251 COVID19 have been compassionately treated at Mount Sinai Hospital with antibody rich plasma from
252 convalescent donors identified with our assays. Last but not least, we believe that our assays could be
253 used to screen health care workers to allow selective deployment of immune medical personnel to care
254 for patients with COVID19. Such a strategy would likely limit nosocomial spread of the virus. More
255 generally, individuals with strong antibody responses could return to normal life, something that might
256 be especially important if a second or third pandemic wave makes quarantine measures again
257 necessary. Importantly, the assumption that individuals with antibodies to the SARS-CoV-2 confer
258 protection from reinfection needs to be confirmed and studies to investigate this should be started as
259 soon as possible. Of course, the generated recombinant proteins are also excellent reagents for vaccine
260 development and can serve as baits for sorting B cells for monoclonal antibody generation. We are
261 making the methods and laboratory reagents widely available to the research community in order to
262 support the global effort to limit and mitigate spread of SARS-CoV-2. A detailed protocol[14] for antigen
263 expression and ELISA set up is available from the corresponding author and plasmids and proteins have
264 so far been shared with more than 200 laboratories worldwide and also deposited at BEI Resources.

265

266 **Methods**

267 **Recombinant proteins**

268 The mammalian cell codon optimized nucleotide sequence coding for the spike protein of SARS-CoV-2
269 isolate (GenBank: MN908947.3) was synthesized commercially (GeneWiz). The receptor binding domain
270 (RBD, amino acid 319 to 541, RVQP….CVNF) along with the signal peptide (amino acid 1-14,
271 MFVF….TSGS) plus a hexahistidine tag was cloned into mammalian expression vector pCAGGS as well as
272 in a modified pFastBacDual vectors for expression in baculovirus system. The soluble version of the spike
273 protein (amino acids 1-1213, MFVF….IKWP) including a C-terminal thrombin cleavage site, T4 foldon
274 trimerization domain and hexahistidine tag was also cloned into pCAGGS. The protein sequence was
275 modified to remove the polybasic cleavage site (RRAR to A) and two stabilizing mutations were
276 introduced as well (K986P and V987P, wild type numbering). Recombinant proteins were produced
277 using the well-established baculovirus expression system and this system has been published in great
278 detail in [17,32,33] including a video guide. Recombinant proteins were also produced in Expi293F cells
279 (ThermoFisher) by transfections of these cells with purified DNA using ExpiFectamine 293 Transfection
280 Kit (ThermoFisher). Supernatants from transfected cells were harvested on day 3 post-transfection by
281 centrifugation of the culture at 4000 g for 20 minutes. Supernatant was then incubated with 6 mls Ni-
282 NTA agarose (Qiagen) for 1-2 hours at room temperature. Next, gravity flow columns were used to
283 collect the Ni-NTA agarose and the protein was eluted. Each protein was concentrated in Amicon
284 centrifugal units (EMD Millipore) and re-suspended in phosphate buffered saline (PBS). Proteins were
285 analyzed on reducing SDS-PAGE. The DNA sequence for all constructs is available from the Krammer
286 laboratory. Several of the expression plasmids and proteins have also been submitted to BEI Resources
287 and can be requested from their web page for free (https://www.beiresources.org/). S1 proteins of
288 NL63 and 229E were obtained from Sino Biologics (produced in 293HEK cells, hexa-histidine tagged). A
289 detailed protocol for protein expression of RBD and spike in mammalian cells is also available.[14]

290

291 **SDS-PAGE**

292 Recombinant proteins were analyzed via a standard SDS-PAGE gel to check protein integrity. One ug of
293 protein was mixed with 2X Laemmli buffer containing 5% beta-mercaptoethanol (BME) at a ratio of 1:1.
294 Samples were heated at 100 °Celsius for 15 minutes and then loaded onto a polyacrylamide gel (5% to
295 20% gradient; Bio-Rad). Gels were stained with SimplyBlue SafeStain (Invitrogen) for 1-2 hours and then
296 de-stained in distilled water overnight.
297
298 **Human samples**
299 Human plasma and serum samples were obtained from a number of different sources.
300 First, de-identified samples from the University of Melbourne (n=3, taken on day 2, 4 and 6 after
301 symptom onset) and University of Helsinki (n=1, day 20 after symptom onset, neutralizing titers 1:160)[13]
302 were used as positive controls. For those, human experimental work was conducted according to the
303 Declaration of Helsinki Principles and according to the Australian National Health and Medical Research
304 Council Code of Practice. All participants provided written informed consent prior to the study. The
305 studies were approved by the Alfred Hospital (ID #280/14) and University of Melbourne (ID #1442952.1,
306 1955465.2) Human Research Ethics Committees, and under research permit for project TYH2018322 of
307 Helsinki University Hospital Laboratory.
308 Second, banked human samples were collected from study participants enrolled in several ongoing IRB
309 approved longitudinal observational study protocols of the Mount Sinai Personalized Virology Initiative.
310 The pre-pandemic serum panel comprised samples selected based on the date of collection (e.g., fall
311 2019) and whether participants had a documented history of viral infection (e.g., dengue virus,
312 hantavirus, Chikungunya virus, coronavirus NL63). All participants agreed to sample banking and future
313 research use. Self-reported ethnicities of the individuals from which samples were tested included
314 Caucasian, Asian, African American and Hispanic. Samples included sera from a participant with acute
315 NL63 infection as determined by the Biofire Respiratory panel. We included serum collected at day 3
316 post symptom onset as well as convalescent serum from the same person (day 30 post symptom onset).
317 These samples served as negative controls given that they were collect prior to SARS-CoV-2 spread in
318 the US. Six subjects were 20-29, 19 were 30-39, 13 were 40-49, 7 were 50-59 years old and six were 60
319 or older. For the mRBD ELISAs sera from additional nine subjects were tested (30-39: 2; 40-49: 4; 50-59:
320 2; 60+: 1). The pre-pandemic panel was complemented by a collection of plasma samples collected from
321 50 HIV-1 infected individuals between 2008 and 2011.
322 The COVID19 panel comprised serum and plasma samples from individuals with severe, mild or
323 asymptomatic SARS-CoV-2 infections. Seven paired serum and plasma samples from patients with
324 COVID19 were used for comparison purposes. These samples were collected between 7 and 31 days
325 post symptom onset.
326
327 **Normal human immunoglobulin (NHIG)**
328 The following NHIG preparations, each prepared from >1000 blood/ plasma donors and intended for
329 intravenous use for medical conditions, were tested in an ELISA to determine if they have reactivity
330 against SARS-CoV-2 spike or RBD: Octagam (M934A8541), Gamunex-c (B2GMD00943, A1GLD01882,
331 B3GLD01223, A1GLD01902, B2GLD01972, B3GGD00143, A1GKE00012 (2 different vials), B2GKD00863,
332 B2GJE00033 (3 different vials)), Gammagard liquid (LE12T292AB, LE12V238AB, LE12V278AD),
333 Gammagard S/D (LE08V027AB, 4 different vials), Gammagard liquid (C19G080AAA, LE12V071AD,
334 LE12V230AB, LE12V115AC, LE12V205AB, LE12VE25AB, LE12V115AC).
335
336 **ELISA**
337 The ELISA protocol was adapted from previously established protocols [34,35]. Ninety-six well plates
338 (Immulon 4 HBX; Thermo Scientific) were coated overnight at 4°Celsius with 50 ul per well of a 2 ug/ml
339 solution of each respective protein suspended in PBS (Gibco). The next morning, the coating solution

340 was removed and 100 ul per well of 3% non-fat milk prepared in PBS with 0.1% Tween 20 (TPBS) was
341 added to the plates at room temperature (RT) for 1 hour as blocking solution. Serum samples were
342 heated at 56°C for 1 hour before use to reduce risk from any potential residual virus in serum. Serial
343 dilutions of serum and antibody samples were prepared in 1% non-fat milk prepared in TPBS. The
344 blocking solution was removed and 100 ul of each serial dilution was added to the plates for 2 hours at
345 RT. Next, the plates were washed thrice with 250ul per well of 0.1% TPBS. Next, a 1:3000 dilution of goat
346 anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (ThermoFisher
347 Scientific) was prepared in 0.1% TPBS and 100 ul of this secondary antibody was added to each well for 1
348 hour. Plates were again washed thrice with 0.1% TBS. Once completely dry, 100 ul of SigmaFast OPD (*o*-
349 phenylenediamine dihydrochloride; Sigma-Aldrich) solution was added to each well. This substrate was
350 left on the plates for 10 minutes and then the reaction was stopped by addition of 50 µL per well of 3 M
351 hydrochloric acid (HCl). The optical density at 490 nanometers was measured via a Synergy 4 (BioTek)
352 plate reader. The background value was set at and optical density (OD) 490nm of 0.11 and area under
353 the curve (AUC) was calculated. AUC values below 1 were assigned a value of 0.5 for graphing and
354 calculation purposes. Data were analyzed using Prism 7 (Graphpad). In some cases endpoint titers were
355 calculated, the endpoint titer being the last dilution before reactivity dropped below and OD 490nm of
356 below 0.11. To determine the impact of heat treatments, paired samples that were heat treated or not
357 treated were analyzed. NHIGs were run similar as serum/plasma samples but with a starting dilution at a
358 concentration of 100 ug/ml. Three non-SARS-CoV-2 reactive human mAbs and CR3022[20-22], a human
359 mAb reactive to the RBD of both SARS-CoV-1 and SARS-CoV-2 were used as controls.
360 To assess the distribution of the different antibody isotypes/subclasses in the samples that reacted well
361 in our standard ELISA, another ELISA was performed with different secondary antibodies [29]. These
362 antibodies include anti-human IgA (α-chain-specific) HRP antibody (Sigma A0295) (1:3,000), anti-human
363 IgM (µ-chain-specific) HRP antibody (Sigma A6907) (1:3,000), anti-human IgG1 Fc-HRP (Southern Biotech
364 9054-05) (1:3,000), anti-human IgG2 Fc-HRP (Southern Biotech #9060-05) (1:3,000), anti-human
365 IgG3hinge-HRP (Southern Biotech 9210-05) (1:3,000), and anti-human IgG4 Fc-HRP (Southern Biotech
366 9200-05).
367

368 **Microneutralization assay**

369 Vero.E6 cells were seeded at a density of 20,000 cells per well in a 96-well cell culture plate in cDMEM.
370 The following day, heat inactivated serum samples (dilution of 1:10) were serially diluted 3-fold in 2X
371 MEM (20% 10× minimal essential medium (Gibco), 4 mM L-glutamine, 0.2% of sodium bicarbonate
372 [wt/vol; Gibco], 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Gibco), 200 U/ml
373 penicillin–200 µ/ml streptomycin (Gibco), and 0.4% bovine serum albumin (MP Biomedical)). The
374 authentic SARS-CoV-2 virus (USA-WA1/2020, GenBank: MT020880) was diluted to a concentration of
375 100 50% cell culture infectious doses ($TCID_{50}$) in 2xMEM. Eighty µL of each serum dilution and 80µL of
376 the virus dilution were added to a 96-well cell culture plate and allowed to incubate for 1 hr at room
377 temperature. cDMEM was removed from Vero.E6 cells and 120 µL of the virus-serum mixture was
378 added to the cells and the cells were incubated at 37°C for 1 hr. After the 1 hr incubation, the virus-
379 serum mixture was removed from the cells and 100 µL of each corresponding serum dilution and 100 µL
380 of 2X MEM containing 2% FBS (Corning) was added to the cells. The cells were incubated for 48 hr at
381 37°C and then fixed with 10% paraformaldehyde (PFA) (Polysciences, Inc) for 24 hr at 4°C. Following
382 fixation, the PFA was removed and the cells were washed with 200 µL of PBS. The cells were then
383 permeabilized by the addition of 150 µL of PBS containing 0.1% Triton X-100 for 15 minutes at room
384 temperature. The plates were then washed three times with PBS containing 0.1% Tween 20 (PBS-T) and
385 blocked in blocking solution (3% milk [American Bio] in PBS-T) for 1 h at room temperature. After

386 blocking, 100 µL of 1C7 (anti-SARS NP antibody generated in house) at a dilution of 1:1000 was added to
387 all wells and the plates were allowed to incubate for 1 hr at room temperature. Plates were then
388 washed three times with PBS-T before the addition of goat anti-mouse IgG-horseradish peroxidase (IgG-
389 HRP; Rockland Immunochemicals) (diluted 1:3000) in blocking solution for 1 hr at room temperature.
390 Plates were then washed three times with PBS-T and the *O*-phenylenediamine dihydrochloride (OPD)
391 substrate (SigmaFast OPD; Sigma-Aldrich) was added. After a 10-minute room temperature incubation,
392 the reaction was stopped by adding 50 µL of 3 M HCl to the mixture. The optical density (OD) was
393 measured at 490 nm on a Synergy 4 plate reader (BioTek). A cutoff value of the average of the OD
394 values of blank wells plus three standard deviations was established for each plate and used for
395 calculating the microneutralization titer.
396

397 **Statistical analysis**

398 Differences between negative controls and positive controls were analyzed using an unpaired t-test.
399 Differences between paired non-treated and heat-treated samples as well as paired serum and plasma
400 samples were analyzed using a paired t-test. Correlation between ELISA titers and neutralization titers
401 were analyzed using Spearman's rank test. Analyses were performed in GraphPad Prism.
402

403 **Acknowledgements**

404 We would like to thank Yong-Zhen Zhang (Fudan University) and Eddie Holmes (University of Sydney) for
405 sharing the sequence of the first SARS-CoV-2 isolate in a very timely manner. We thank Jill Garlick and
406 Janine Roney (Alfred Hospital, Melbourne) for data and specimen collection and Nouran Aboelregal for
407 making lots of different NHIGs products (Mount Sinai) available. We are also thankful to Genewiz for
408 speeding up gene synthesis for this project, and being very accommodating to our needs. Furthermore,
409 we want to thank Donna Tidmore for help with ordering primers with near light speed and and finally
410 Susie (Changsu) Dong for commuting to New Jersey on several occasions to pick up reagents from
411 Genewiz. We also thank the study participants for providing biospecimen for research purposes and the
412 Conduits: Mount Sinai Health System Translational Science Hub (NIH grant U54TR001433) for supporting
413 sample collection. The work of the Personalized Virology Initiative is supported by institutional funds
414 and philanthropic donations. This work was partially supported by the NIAID Centers of Excellence for
415 Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C, the Australian National
416 Health and Medical Research Council (NHMRC) NHMRC Program Grant (1071916) and NHMRC Research
417 Fellowship Level B (#1102792), the Academy of Finland and Helsinki University Hospital Funds
418 (TYH2018322). Furthermore, we thank our generous community for providing essential funds and
419 support for our SARS-CoV-2 and COVID-19 research efforts. The following reagent was deposited by the
420 Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-
421 Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. Finally, we want to thank all the study
422 participants for their contribution to research. We wish the patients with COVID19 a speedy recovery.

423 **Data availability statement**

424 The data shown in the manuscript is available upon request from the corresponding author.

425 **Conflict of interest**

426 Mount Sinai is in the process of licensing out assays based on the assays described here to commercial
427 entities.

428

429 **References**

430 1. Wu, F., *et al.* A new coronavirus associated with human respiratory disease in China. *Nature*
431 (2020).
432 2. Zhou, P., *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin.
433 *Nature* (2020).
434 3. Gorbalenya, A.E., *et al.* The species Severe acute respiratory syndrome-related coronavirus:
435 classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology* (2020).
436 4. Chu, D.K.W., *et al.* Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak
437 of Pneumonia. *Clin Chem* (2020).
438 5. Corman, V.M., *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro*
439 *Surveill* **25**(2020).
440 6. Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for
441 SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* (2020).
442 7. Wrapp, D., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
443 *Science* (2020).
444 8. Walls, A.C., *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
445 *Cell* (2020).
446 9. Berry, J.D., *et al.* Neutralizing epitopes of the SARS-CoV S-protein cluster independent of
447 repertoire, antigen structure or mAb technology. *MAbs* **2**, 53-66 (2010).
448 10. Liu, W., *et al.* Two-year prospective study of the humoral immune response of patients with
449 severe acute respiratory syndrome. *J Infect Dis* **193**, 792-795 (2006).
450 11. Callow, K.A., Parry, H.F., Sergeant, M. & Tyrrell, D.A. The time course of the immune response to
451 experimental coronavirus infection of man. *Epidemiol Infect* **105**, 435-446 (1990).
452 12. Choe, P.G., *et al.* MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea,
453 2015. *Emerg Infect Dis* **23**, 1079-1084 (2017).
454 13. Haveri, A., *et al.* Serological and molecular findings during SARS-CoV-2 infection: the first case
455 study in Finland, January to February 2020. (Eurosurveillance, 2020).
456 14. Stadlbauer, D., *et al.* A detailed protocol for a serological assay to detect SARS-CoV-2
457 seroconversion in humans: antigen production and test setup. (submitted).
458 15. Pallesen, J., *et al.* Immunogenicity and structures of a rationally designed prefusion MERS-CoV
459 spike antigen. *Proc Natl Acad Sci U S A* **114**, E7348-E7357 (2017).
460 16. Kirchdoerfer, R.N., *et al.* Pre-fusion structure of a human coronavirus spike protein. *Nature* **531**,
461 118-121 (2016).
462 17. Krammer, F., *et al.* A carboxy-terminal trimerization domain stabilizes conformational epitopes
463 on the stalk domain of soluble recombinant hemagglutinin substrates. *PLoS One* **7**, e43603
464 (2012).
465 18. Margine, I., Palese, P. & Krammer, F. Expression of Functional Recombinant Hemagglutinin and
466 Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression
467 System. *J Vis Exp* (2013).
468 19. Li, F., Li, W., Farzan, M. & Harrison, S.C. Structure of SARS coronavirus spike receptor-binding
469 domain complexed with receptor. *Science* **309**, 1864-1868 (2005).
470 20. Tian, X., *et al.* Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-
471 specific human monoclonal antibody. *Emerg Microbes Infect* **9**, 382-385 (2020).

472 21. ter Meulen, J., *et al.* Human monoclonal antibody combination against SARS coronavirus:
473 synergy and coverage of escape mutants. *PLoS Med* **3**, e237 (2006).
474 22. Yuan, M., *et al.* A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-
475 2 and SARS-CoV. *Science* (2020).
476 23. Wu, K., Li, W., Peng, G. & Li, F. Crystal structure of NL63 respiratory coronavirus receptor-
477 binding domain complexed with its human receptor. *Proc Natl Acad Sci U S A* **106**, 19970-19974
478 (2009).
479 24. Khan, S., *et al.* Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses
480 and SARS-CoV-2 Using Coronavirus Antigen Microarray. *bioRxiv*, 2020.2003.2024.006544 (2020).
481 25. Li, Q., *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected
482 Pneumonia. *N Engl J Med* (2020).
483 26. Tseng, C.T., *et al.* Immunization with SARS coronavirus vaccines leads to pulmonary
484 immunopathology on challenge with the SARS virus. *PLoS One* **7**, e35421 (2012).
485 27. Gonzalez-Reiche, A.S., *et al.* Introductions and early spread of SARS-CoV-2 in the New York City
486 area. *medRxiv*, 2020.2004.2008.20056929 (2020).
487 28. Nachbagauer, R., *et al.* Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin
488 Stalk-Reactive Antibodies in Humans. *MBio* **7**(2016).
489 29. Rajendran, M., *et al.* Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children,
490 Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin. *mBio*
491 **8**(2017).
492 30. Hu, X., *et al.* Heat inactivation of serum interferes with the immunoanalysis of antibodies to
493 SARS-CoV-2. *medRxiv*, 2020.2003.2012.20034231 (2020).
494 31. Shen, C., *et al.* Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
495 *JAMA* (2020).
496 32. Amanat, F., *et al.* Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New
497 World Arenaviruses. *mSphere* **3**(2018).
498 33. Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and
499 neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression
500 system. *J Vis Exp*, e51112 (2013).
501 34. Amanat, F., Meade, P., Strohmeier, S. & Krammer, F. Cross-reactive antibodies binding to H4
502 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model.
503 *Emerg Microbes Infect* **8**, 155-168 (2019).
504 35. Wohlbold, T.J., *et al.* Broadly protective murine monoclonal antibodies against influenza B virus
505 target highly conserved neuraminidase epitopes. *Nat Microbiol* **2**, 1415-1424 (2017).

506

507 **Figure legends**

508

509 **Figure 1: Constructs for recombinant protein expression. A** Visualization of the trimeric spike protein of
510 SARS-CoV-2 based on PBD # 6VXX using Pymol.[8] One monomer is colored in dark blue while the
511 remaining two monomers are held in light blue. The receptor binding domain (RBD) of the dark blue
512 trimer is highlighted in red. **B** Schematic of the wild type full length spike protein with signal peptide,
513 ectodomain, receptor binding domain, furin cleavage site, S1, S2, and transmembrane and endodomain
514 domain indicated. **C** Schematic of the soluble trimeric spike. The polybasic/furin cleavage site (RRAR)
515 was replaced by a single A. The transmembrane and endodomain were replaced by a furin cleavage site,
516 a T4 foldon tetramerization domain and a hexahistidine tag. Introduction of K986P and V987P has been

517 shown to stabilize the trimer in the pre-fusion conformation. **D** Schematic of the soluble receptor
518 binding domain construct. All constructs are to scale. **E** Reducing SDS PAGE of insect cell and mammalian
519 cell derived soluble trimerized spike protein (iSpike and mSpike). **F** Reducing SDS PAGE of insect cell
520 derived and mammalian cell derived recombinant receptor binding domain (iRBD and mRBD).

521 **Figure 2: Reactivity of control and SARS-CoV-2 convalescent sera to different spike antigens. A-D**
522 Reactivity to insect cell derived RBD (iRBD), mammalian cell derived RBD (mRBD), insect cell derived
523 soluble spike protein (iSpike) and mammalian cell derived soluble spike protein (mSpike). Sera from
524 SARS-CoV-2 infected individuals are shown in red. One sample, shown in green, is a convalescent serum
525 sample post NL63 infection. **E-F** shows data from the same experiment but graphed as area under the
526 curve (AUC) to get a better quantitative impression. The n for the control samples is 50 except for the
527 iRBD where it is 59. Statistics were performed using an unpaired two-tailed student's t-test in Graphpad
528 Prism. **I-G** shows reactivity of the 50 negative control samples from A-F against spike protein from
529 human coronaviruses 229E and NL63.

530 **Figure 3: Figure 3: Human normal immunoglobulin preparations and historic sera from HIV+ patients**
531 **do not react with the SAR-CoV-2 spike. A-B** Reactivity of 21 different pools of human normal
532 immunoglobulin (HNIG) preparations (27 different vials) to mRBD and mSpike of SARS-CoV-2. MAb
533 CR3022 was used as positive control, three different irrelevant human mAbs were used as negative
534 control. **C-D** shows reactivity of historic samples from 50 HIV+ individuals to mRBD and mSpike of SARS-
535 CoV-2. Both HNIG and serum samples from HIV+ donors were collected before the SARS-CoV-2
536 pandemic.

537 **Figure 4: Effect of heat treatment and serum versus plasma on assay performance. A-B** Reactivity of
538 paired non-treated serum and heat treated serum samples to mRBD and mSpike of SARS-CoV-2 (n=5). **C-**
539 **D** Reactivity of paired serum and plasma samples to mRBD and mSpike of SARS-CoV-2 (n=7). Statistics
540 were performed using a paired student's t-test in Graphpad Prism.

541 **Figure 5: Isotypes and subtypes of antibodies from COVID19 patients to the soluble spike protein and**
542 **correlation between ELISA and microneutralization titer.** (**A**) Mammalian cell derived spike protein was
543 used to study isotype/subclass distribution of antibodies (n=13 positive samples). (**B**) Correlation
544 between ELISA titers and microneutralization titers (n=12, the three samples from negative control sera
545 overlap and are displayed as single point). Statistics were performed using Pearson's rank test in
546 Graphpad Prism.


A
Receptor binding domain
(amino acid 319-541)
Membrane distal
Membrane proximal
E
ladder
iSpike
mSpike
245 kDa
190 kDa
135 kDa
100 kDa
80 kDa
58 kDa
46 kDa
32 kDa
25 kDa
22 kDa
17 kDa
F
ladder
iRBD
mRBD
B
Wild type spike
N
Receptor binding domain
(amino acid 319-541)
S1
Polybasic cleavage site
(amino acid 682-685/RRAR)
S2
P1213
C
Signal peptide
(amino acid 1-14)
Ectodomain
(amino acid 15-1213)
Transmembrane- and endodomain
(amino acid 1214-1273)
C
Stabilized, soluble spike
RRAR to A
K986P and V987P
Signal peptide
(amino acid 1-14)
Ectodomain
(amino acid 15-1213)
Thrombin cleavage site, T4 trimerization domain and 6xhis tag
D
Soluble receptor binding domain
Signal peptide
(amino acid 1-14)
Receptor binding domain
(amino acid 319-541)
6xhis tag


A
iRBD
B
mRBD
C
iSpike
D
mSpike
OD (490 nm)
Reciprocal dilution
post NL63
other negative control samples
SARS-CoV-2 samples
E
iRBD
F
mRBD
G
iSpike
H
mSpike
Area under curve (AUC)
p<0.0001
Control samples
SARS-CoV-2 seroconverters
I
reactivity of negative controls
to hCoV 229E spike
J
reactivity of negative controls
to hCoV NL63 spike
neg. contr. #1-50


A
mRBD
NHIG preparation reactivity
OD (490 nm)
2.5
2.0
1.5
1.0
0.5
0.0
100
10
1
0.1
ug/ml
B
mSpike
NHIG preparation reactivity
OD (490 nm)
2.5
2.0
1.5
1.0
0.5
0.0
100
10
1
0.1
ug/ml
NHIG preparations 1-27
Neg. contr. mAb 1
Neg. contr. mAb 2
Neg. contr. mAb 3
mAb CR3022
C
mRBD
reactivity of historic HIV+ samples
OD (490 nm)
2.5
2.0
1.5
1.0
0.5
0.0
100
1000
10000
Reciprocal dilution
D
mSpike
reactivity of historic HIV+ samples
OD (490 nm)
2.5
2.0
1.5
1.0
0.5
0.0
100
1000
10000
Reciprocal dilution
HIV+ samples #1-50


A
mRBD
non-treated versus heat inactivated
p=0.1031
Area under curve (AUC)
10000
1000
100
10
non-inactivated
56°C for 60min
B
mSpike
non-treated versus heat inactivated
p=0.1991
Area under curve (AUC)
10000
1000
100
10
non-inactivated
56°C for 60min
C
mRBD
serum versus plasma
p=0.0311
Area under curve (AUC)
10000
1000
100
10
Serum
Plasma
D
mSpike
serum versus plasma
p=0.4448
Area under curve (AUC)
10000
1000
100
10
Serum
Plasma


A
mSpike isotyping/subtyping
Area under curve (AUC)
100000
10000
1000
100
10
1
0.1
IgG1
IgG2
IgG3
IgG4
IgM
IgA
B
Correlation
mSpike ELISA and microneutralization assay
microneutralization IC50
10000
1000
100
10
1
0.1
n=3 neg. contr.
Pearson r = 0.9279
p<0.0001
10
100
1000
10000
100000
mSpike ELISA endpoint titer